MISSION STATEMENT: Delivery on the Promise of Pulmonary Drug Delivery

TYPE OF COMPANY: Inhaled drug delivery/Biotechnology

ADDRESS: 630 Davis Drive, Suite 120, Durham, NC 27713

PHONE NUMBER: (919) 313-1290

WEB SITE: www.orieltherapeutics.com

MANAGEMENT TEAM MEMBERS (include a brief background about each executive, with their title):
Paul J. Atkins, PhChief Executive Officer
Paul joined Oriel from GlaxoSmithKline where he was involved with the development and commercialization of inhaled delivery systems, most recently as Director, Delivery Systems in the Global Respiratory Therapeutic Development group. With over 20 years in the pharmaceutical industry in both the United Kingdom and the United States, he is a recognized leader in the inhaled drug delivery field. During his time with GSK, Paul’s accomplishments included establishing and building the Inhaled Product Development Group in the United States, as well as leading a number of global technical development programs, particularly the development of HFA MDIs. Paul is also a founder of Oriel Therapeutics.

Professor Anthony J. Hickey, PhD.-Chief Scientific Officer
Dr. Hickey’s research in the field of pharmaceutical powder behavior over a period of more than a decade, inspired by his own struggles with asthma since childhood, is the foundation for Oriel’s technology. Dr. Hickey is currently Professor of Drug Delivery and Disposition at the University of North Carolina, Chapel Hill, and is internationally reputed in the field of inhalation technology. He has been a consultant to the pharmaceutical industry for almost 20 years. Dr. Hickey is a founder of Oriel Therapeutics.

Thomas J. Sekel…Vice President, Administration – Chief Financial Officer
Tom is a senior financial manager who has more than 25 years experience working with national and international corporations. Prior to joining Oriel, he served as Vice President, Finance, for eight years with Bespak, Inc., a multinational manufacturing company that supplies drug delivery devices to the pharmaceutical industry for the treatment of respiratory diseases and emerging biopharmaceutical markets. During his eight years with Bespak, Tom was directly involved in developing a strategic plan to align and focus the total organization with corporate goals. He has also worked with Kanthal Corporation, Electro-Alloys Corporation, Qualitron Corporation, and Nestle USA.

John Denny, Vice President, Product Development
John has 15 years of experience leading multinational teams to design and manufacture products for the global marketplace. Prior to joining Oriel, John was a director at GlaxoSmithKline responsible for all new device projects for the respiratory business. Whilst at GSK John developed and implemented a program to improve cross-functional input for new product development, ensuring devices meet design for manufacturing requirements. John was also founder and president of Develotech, Inc., a design company created to improve new product development lead times for the manufacturing and service industries. In addition, he has held key engineering positions at Hubbell, Inc. and Crouse Hinds Company.

Timothy M. Crowder, PhD … Vice President, Powder Technology
Timm completed his Ph.D. in the Department of Biomedical Engineering at the University of North Carolina, Chapel Hill under the supervision of Professor Anthony Hickey. His dissertation research, concerning the physics of powder flow and its application to dispersion in dry powder inhalers, forms the basis for Oriel’s technology platform. Timm’s research at UNC included the direction of an industrially-sponsored nasal dry powder vaccine project and developing a prototype dry powder inhaler and dispersion mechanism. His prior experience was in the areas of solid state physics and semiconductor research. Timm is a founder of Oriel Therapeutics.

    BOARD MEMBERS:

  • P. J. Atkins, PhD
  • M. Barron
  • F. Eshelman
  • A. J. Hickey
  • T. Crowder

INVESTORS (and amounts raised, if possible):
To date we have raised over $3.0M and our primary investors are PPD (Wilmington) and Trudell Medical (London, Ontario).

REVENUES:
In 2004 we had revenues of approx. $0.5M .

YEAR ESTABLISHED: 2002

NUMBER OF EMPLOYEES: 7 full time with an additional 6 part-time/consultants